Shanghai, China Related Funds
| Fund Name | Location |
| Augeo Marketing | Minnesota, Saint Paul, United States |
| Circle Financial Group | New York, New York, United States |
| Confluent Medical Technologies | California, Fremont, United States |
| Curo Capital | - |
| GEM Capital | Switzerland, Zürich, Zurich |
| Hangzhou Longli Touzi Guanli Co., Ltd | China, Hangzhou, Zhejiang |
| ITI Venture Capital Partners | Israel, Tel Aviv, Tel Aviv District |
| Jotter Ventures | California, Menlo Park, United States |
| London Stock Exchange Group | England, London, United Kingdom |
| MAKOTO | Japan, Miyagi Prefecture, Sendai |
| Matrimony.com | Chennai, India, Tamil Nadu |
| Mt Vernon Investments | - |
| Skycore | Massachusetts, United States, Waltham |
| TMWRK | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Zhuanma Biotech | 16 Apr 2024 | Shanghai, Shanghai, China | |||
Rebbeca Med | $10M | 01 Feb 2024 | Shangcheng District, Zhejiang, China | ||
Phrontline Biopharma | 01 Jan 2024 | Shanghai, Shanghai, China | |||
Med-Vision | 11 Jan 2023 | Shangcheng District, Zhejiang, China | |||
VelaVigo | 01 Jan 2023 | Shanghai, Shanghai, China | |||
Leadinno Medical Valley | $19M | 31 Aug 2022 | Beijing, Beijing, China | ||
Degron Therapeutics | $22M | 09 Jun 2022 | Shanghai, Shanghai, China | ||
Weimi Bio-Tech | $17M | 20 May 2022 | Yuexiu District, Guangdong Province, China | ||
Med-Vision | $3M | 02 Apr 2022 | Shangcheng District, Zhejiang, China |
– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Zhuanma Biotech | 16 Apr 2024 | Shanghai, Shanghai, China | |||
Rebbeca Med | $10M | 01 Feb 2024 | Shangcheng District, Zhejiang, China | ||
Phrontline Biopharma | 01 Jan 2024 | Shanghai, Shanghai, China | |||
Med-Vision | 11 Jan 2023 | Shangcheng District, Zhejiang, China | |||
VelaVigo | 01 Jan 2023 | Shanghai, Shanghai, China | |||
Leadinno Medical Valley | $19M | 31 Aug 2022 | Beijing, Beijing, China | ||
Degron Therapeutics | $22M | 09 Jun 2022 | Shanghai, Shanghai, China | ||
Weimi Bio-Tech | $17M | 20 May 2022 | Yuexiu District, Guangdong Province, China | ||
Med-Vision | $3M | 02 Apr 2022 | Shangcheng District, Zhejiang, China |
